Home avatar

Dr Rahul Khanna

Psychiatrist and Health Executive

Digital Psychosocial Interventions

Abstract

People with complex mental health needs in Australia face substantial psychosocial challenges across multiple life domains, including social and vocational functioning, self-efficacy, and general quality of life. These needs often remain unmet in a mental health system that is largely structured to focus on time-limited symptom reduction, which assumes a linear recovery path that may not match lived experience. Multidimensional support that blends clinical care with digital psychosocial programmes carry the potential to strengthen the range of supports to support long-term recovery in people with complex mental health needs. Self-guided programmes include peer-led online forums, often paired with psychoeducation modules to enhance effectiveness. Guided programmes include a range of additional channels including one-to-one coaching, and telehealth groups. Evidence is emerging for the effectiveness of both self-guided and guided online programmes in improving social isolation, self-confidence, wellbeing, employment and education opportunities for people facing a range of severe and enduring mental illnesses: including schizophrenia, bipolar disorder and complex trauma. While engagement in these programmes can vary, satisfaction and acceptability is usually very high, providing practitioners with a wider range of options to help clients move beyond symptom reduction and satisfy a broader spectrum of psychosocial needs.

The Silexan in the Treatment Of Posttraumatic stress disorder (STOP) trial - protocol for a 12-week randomised controlled trial of adjunctive Silexan for PTSD

Abstract

Background

Posttraumatic stress disorder (PTSD) is a common and potentially debilitating psychiatric disorder. Current and emerging evidence-based treatments for PTSD have significant limitations. Silexan is an orally administered lavender oil preparation whose main constituents are the monoterpenoids linalool and linalyl acetate. It has a novel pharmacodynamic profile that includes inhibition of voltage-gated calcium channels and promotion of neuroplasticity. Silexan is effective in the treatment of Generalized Anxiety Disorder, subthreshold anxiety disorders and mild-to-moderate Major Depressive Disorder. It has an excellent safety and tolerability profile. Promising pilot data suggest that Silexan may be effective for PTSD. The Silexan in the Treatment Of Posttraumatic stress disorder (STOP) trial aims to investigate the effectiveness of adjunctive Silexan in PTSD.

The chatbot will see you now

I enjoyed the discussions with AusDoc journalist Bella Rough for this piece.


Read the article here (free but login required) www.ausdoc.com.au/news/the-chatbot-will-see-you-now-the-darkness-in-the-soul-of-machine-therapy/ card image

Citation
Rough, B. (2025). ‘The chatbot will see you now - the darkness in the soul of machine therapy’. AusDoc, Melbourne, Australia.